A single-center, randomized, placebo-controlled single & multiple ascending dose study in healthy subjects to study the safety, tolerability, food effect, pharmacokinetics and target engagement of the second-generation O-GlcNAcase inhibitor ASN121151

Project Number
ADDF-1
Agency/Funding Organization
Alzheimer's Drug Discovery Foundation
Funding Year
2020
View Full Project Details for A single-center, randomized, placebo-controlled single & multiple ascending dose study in healthy subjects to study the safety, tolerability, food effect, pharmacokinetics and target engagement of the second-generation O-GlcNAcase inhibitor ASN121151
Research Categorization
Primary Disease / Condition
Alzheimer's Disease
CADRO
Category C. Translational Research and Clinical Interventions
7. Early-stage Clinical Drug Development (Phase I and II Clinical Trials)
j. Metabolism and Bioenergetics
Researcher and Organization
Principal Investigator
Beher, Dirk
Principal Investigator First Name
Dirk
Principal Investigator Last Name
Beher
Awardee Organization
Asceneuron SA
Contact PI Country
Switzerland
Project Detail
FY Overall Cost
$2,200,000
Funding Organization
Agency/Funding Organization
Alzheimer's Drug Discovery Foundation
Funding Organization Country
United States
Program Official
ADDF Grants Management

You might be interested in other related resources and tools...